CVI-2742 / CVI Pharma - LARVOL DELTA

PRECLINICAL CHARACTERIZATION OF CVI-2742: A HIGHLY SELECTIVE, LIVER-TARGETED THR-β FULL AGONIST WITH ROBUST EFFICACY AND SAFETY IN MASH MODELS (AASLD 2025) - "Background: Thyroid hormone receptor beta (THR-β) selective agonists represent a breakthrough in metabolic dysfunction-associated steatohepatitis (MASH) treatment, with Resmetirom (MGL-3196) being the first FDA-approved THR-β agonist that avoids cardiac THR-α activation. CVI-2742 exhibits best-in-class potential as a liver-targeted THR-β full agonist, combining high potency, robust hepatic selectivity, and an outstanding safety profile. Its ability to ameliorate MASH pathology and dyslipidemia at low doses, coupled with favorable PK and toxicology data, strongly supports its advancement into clinical trials for MASH therapy."

Preclinical • Dyslipidemia • Fibrosis • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

CVI-2742, A NOVEL THR-BETA SELECTIVE AGONIST, EXHIBITS ENHANCED LIVER-TARGETING PROPERTIES IN NON-HUMAN PRIMATES AND POTENT ANTI-NASH ACTIVITY IN MOUSE NASH MODEL (AASLD 2024) - "Background: Resmetirom has shown promising results in treating non-alcoholic steatohepatitis (NASH) by selectively activating thyroid hormone receptor-beta (THR-β) in liver tissue. These findings highlight CVI-2742 as a promising candidate for NASH therapy due to its liver-targeted mechanism and potent anti-NASH effects in preclinical models. The excellent pharmacokinetic profiles observed in non-human primates and rodent models support the further development of CVI-2742 towards human clinical studies for NASH treatment."

Preclinical • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Oncology

CVI-2742, a highly potent and liver-targeted new generation THR-β selective agonist, strongly reduces liver steatosis and bridging fibrosis in rodent MASH model (EASL-ILC 2024) - No abstract available

Preclinical • Fibrosis • Immunology • Metabolic Dysfunction-Associated Steatohepatitis